Roivant Sciences (NASDAQ:ROIV) Raised to “Strong-Buy” at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Roivant Sciences (NASDAQ:ROIV) to a strong-buy rating in a report issued on Tuesday morning,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Tuesday, February 11th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $18.08.

Roivant Sciences Price Performance

Shares of Roivant Sciences stock opened at $10.32 on Tuesday. Roivant Sciences has a fifty-two week low of $9.76 and a fifty-two week high of $13.06. The firm has a fifty day moving average price of $11.01 and a two-hundred day moving average price of $11.57. The company has a market cap of $7.36 billion, a PE ratio of -68.80 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. Analysts expect that Roivant Sciences will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO Eric Venker sold 218,041 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total transaction of $2,271,987.22. Following the completion of the transaction, the chief operating officer now owns 896,869 shares in the company, valued at approximately $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Sciences Ltd. Roivant acquired 16,845,010 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were purchased at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at approximately $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders sold 2,388,170 shares of company stock valued at $27,612,299. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Roivant Sciences during the fourth quarter valued at approximately $194,000. Jefferies Financial Group Inc. acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $473,000. GF Fund Management CO. LTD. acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $181,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Roivant Sciences by 4.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock valued at $28,528,000 after buying an additional 104,288 shares during the period. Finally, Zimmer Partners LP acquired a new position in shares of Roivant Sciences in the fourth quarter valued at approximately $2,992,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.